Vincristine sulfate

Catalog No.S1241 Synonyms: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Size Price Stock Quantity  
In DMSO USD 90 In stock
USD 70 In stock
USD 270 In stock
USD 870 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

    Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

    for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent  experiments and of f our replicates in each experiment.

    Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHv0boUxNTBwNTFOwG0> NWn6T2xyOjRiaB?= MojT[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MUGyOVY3Ozd4OR?=
HepG2-HBV1.1 NXnLVpoxSXCxcITvd4l{KEG|c3H5 NV;5d5l2OC1yLkWg{txO M1i5UFI1KGh? MY\pcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 M4\TT|I2PjZ|N{[5
HepG2.2.15 NGLve4ZHfW6ldHnvckBCe3OjeR?= NVj1cXR3OC5zIN88US=> MVuyOEBp MWXwdo9ud3SnczDo[ZBifGm2aYOgRkB3cXK3czDwdo91\WmwIHX4dJJme3Orb36= NFi3TFQzPTZ4M{e2PS=>
HepG2-HBV1.1 NXXKfZpOTnWwY4Tpc44hSXO|YYm= NFvV[WoxNjFizszN MVKyOEBp NHruVYlxem:vb4Tld{Bp\XCjdHn0bZMhSiC4aYL1d{Bxem:2ZXnuJIV5eHKnc4Ppc44> NYLCcmdbOjV4NkO3Olk>
HepG2-HBV1.1 NH;DOYRHfW6ldHnvckBCe3OjeR?= MYiwMlEh|ryP MVq0PEBp MXTwdo9ud3SnczDj[YxtKGW6Y4LleIlwdiCxZjDo[ZBifGm2aYOgRkB3cXK3czDueYNt\W:lYYDzbYR{KGmwc4TlZYQhd2ZiaHXwZZRqfGm|IFKgeolzfXNiRHHu[UBx[XK2aXPs[ZM> MoTrNlU3PjN5Nkm=
HepG2-HBV1.1 NHzRVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3sUIlpOC5zIN88US=> MnH1NU02KGR? MYrpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjD0bY1mKGSncHXu[IVvfGy7 M1fBN|I2PjZ|N{[5
HepG2-HBV1.1 NInKTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInN[pExNjFizszN MVmxMVUh\A>? MnTtbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36geIlu\SCmZYDlcoRmdnSueR?= Mlm1NlU3PjN5Nkm=
HepG2-HBV1.1 NYi2fnlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELsWHIxNjFizszN MYmxNk04OiCq NGDGW|NqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U> M1P4S|I2PjZ|N{[5
HepG2-HBV1.1 NXS1[XY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXiwMlEh|ryP NHPaR5IyOi15MjDo M4LLc4lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhWy2yaHHz[S=> NELrNlYzPTZ4M{e2PS=>
Raji NHm4PIFHfW6ldHnvckBCe3OjeR?= NIfCRYUxNjYEoN88US=> NGP2TWM4OiCq MmTrZYJwdGm|aHXzJIF2fG:yaHHnfeKh NIj5emIzPTR2NkO3Oy=>
SK-MEL-28  M3jn[WZ2dmO2aX;uJGF{e2G7 M1vR[lMxKG6P MX22JIg> NIPNWllqdmS3Y3XzJGcz6oDVTTDj[YxtNWO7Y3zlJIFzemW|dB?= NXr1Z3Z[OjV|MUOwNVA>
H157 M{Pve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLtTWM2OD1zLkCzJOKyKDBwMESgcYl2Ok1? NY\BXYNFOjV{NUe5NVE>
Jurkat NIPhNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTvNU0{KG6P MkfBOFjDqGh? NVr0W5gzTE2VTx?= NXjETIhl\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? NIDv[oQzPTF3NkG0Oi=>
CEM MmXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;GNU0{KG6P NGHpWFc1QMLiaB?= M{LGVWROW09? Mori[IVkemWjc3XzJJZq[WKuZTDj[YxtKG63bXLldpMh\G:|ZTDk[ZBmdmSnboTsfS=> NY\rVZVoOjVzNU[xOFY>
P12 NELwcmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHYNU0{KG6P MnH2OFjDqGh? NYnYUldlTE2VTx?= MYnk[YNz\WG|ZYOgeoli[mynIHPlcIwhdnWvYnXyd{Bld3OnIHTldIVv\GWwdHz5 NY[4V5NpOjVzNU[xOFY>
KB MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMEC0PUDDuSByLkCwNFEh|ryP MVOyOVA2QDV{Nh?=
KBv200 (ABCB1) Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDRdnFJUUN3ME2wMlM1PjJiwsGgNE4xODZ4IN88US=> MU[yOVA2QDV{Nh?=
SUDHL6  MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PNbFHjiIoQvF2= MnrQOFgwPzJiaB?= MknBbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> MmLSNlQ6PjF4MES=
SUDHL6  M2fnPWZ2dmO2aX;uJGF{e2G7 MX6x5qCK|ryP NX[3U2tsPzJiaB?= NGC1VllqdmS3Y3XzJJNq\26rZnnjZY51KGGyb4D0c5Rq[yCvb4LwbI9td2e7IHPoZY5o\XNiY3;0doV{fGWmIIfpeIghSkOOMUHBJJNqWk6D MXOyOFk3OTZyNB?=
HCT-116 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;HTVUxRTVibl2= MVyyOFkzPzh3Nx?=
SKNBe2C NUnBXoRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTN{LklCtVQvOCCwTR?= M{HWcFI1QTJzOUKw
IGNR91 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIqxSZNKSzVyPUK0MlPDuTFwNzDuUS=> M2\5TVI1QTJzOUKw
SKNAS MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvYe2ozUUN3ME2xMlXDuTBwMjDuUS=> NX;oeHpSOjR7MkG5NlA>
LAN1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnOPFJKSzVyPUKuN:KyOC5{IH7N M2rrNVI1QTJzOUKw
SHSY5Y MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\HVmlEPTB;OD6yxtExNjZibl2= M3raWVI1QTJzOUKw
A549-WT NITq[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjmPYFmUUN3ME2xPU41OzdiwsGgNE42QTRiIH7N MVuyOFg2QDh{Nx?=
A549-R M3vvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTF{LkG3PEDDuSByLkOzN{Ahdk1? M3u2RVI1QDV6OEK3
MCF-7-WT MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFG3NIdKSzVyPUG3Mlc2OiEEsTCwMlIyQCBibl2= MWWyOFg2QDh{Nx?=
MCF-7-R NFm1UHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu4fVlKSzVyPUWuOVM6KMLzIECuNVQ1KCCwTR?= MoTLNlQ5PTh6Mke=
A549-R MVnDfZRwfG:6aXPpeJkhSXO|YYm= NWK5SHZ6UUN3ME2xNk4yPzhiwsGgNE4{OzNibl2= MorVNlQ5PTh6Mke=
MCF-7-R NEHHTGREgXSxdH;4bYNqfHliQYPzZZk> NVTae3lpUUN3ME21MlU{QSEEsTCwMlE1PCCwTR?= M{GxZ|I1QDV6OEK3
SW620 NUTub4dPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[zemlEPTB;Nz64NEDDuSByLkC4JI5O NWG2b481OjR5Mk[3N|k>
SW620/AD300 M1v4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS3V4VKSzVyPUmwPU43OCEEsTC4MlkyKG6P MYWyOFczPjd|OR?=
HEK293/pcDNA3.1 NV;ZXJJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HjcWlEPTB;MT60OUDDuSByLkKwJI5O M3joVlI1PzJ4N{O5
HEK293/ABCC1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTF7LkK5JOKyKDJwMEigcm0> M2DXPVI1PzJ4N{O5
TCC M3SzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3hdmc2OjRiaB?= MnPZTWM2OD15MDDuUS=> NYD2XG1nOjR5MU[5OFQ>
TCC M4PGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVm0PEBp NYj1d5UxUUN3ME21NEBvVQ>? MWGyOFcyPjl2NB?=
HepG2/ADM MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmmzTWM2OD1{Lke4OlPDuTBwMkO3NUDPxE1? NGrDUWUzPDdyNEW1Oi=>
HepG2 M{XtRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHkTWM2OD1yLkCxNVXDuTBwMECxO{DPxE1? MYSyOFcxPDV3Nh?=
MCF-7/ADR M{HROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjtTWM2OD12LkS4NlbDuTBwMkC3NEDPxE1? NVnwNYJGOjR5MES1OVY>
MCF-7 NV;sR|dXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\aVWlEPTB;MD6wNVU6yrFyLkCwOlIh|ryP NH;GUWYzPDdyNEW1Oi=>
A-172  NF7RVWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjjS2UxNjIEoN88US=> NIO3enEzPC95MjDo MXXpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 NILTc3ozPDV|MEKzOS=>
U-251MG NXrCVWxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[wMlHDqM7:TR?= M2fCUFI1Nzd{IHi= MVjpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 NEnWRVAzPDV|MEKzOS=>
DLD-1 MmjhSpVv[3Srb36gRZN{[Xl? M3[zRVExOCCwTR?= MUK0PEBp MUXwdo9ud3SnczDSWW5ZOyCmZX3leIh6dGG2aX;uxsA> NWLnZ3J5OjR2MEO0OVM>
CCD18Co NVLiUGM3TnWwY4Tpc44hSXO|YYm= M1jkcFExOCCwTR?= MkTROFghcA>? NIq2NoFxem:vb4Tld{BTXU6[MzDk[Y1mfGi7bHH0bY9vyqB? MV:yOFQxOzR3Mx?=
DLD-1 MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnuNE0yODByIH7N Mnm2OFghcA>? MlzKbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MYqyOFQxOzR3Mx?=
CCD18Co NGDoeo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7EbokzOC1zMECwJI5O MorCOFghcA>? Mk\KbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M3rIRlI1PDB|NEWz
HepG2 Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3wNlQhcA>? MY\JR|UxRTV{LkZihKnPxE1? NIfCelczPDN2MU[4PC=>
HEK293/pcDNA3.1 NGrz[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfTTWM2OD1yLkCwOOKyOC5yMECzJO69VQ>? NWnCeXFsOjR{OES3PFM>
HEK293/MRP1 M{flXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMEW1xtExNjBzMkCg{txO MUmyOFI5PDd6Mx?=
Ramos NFzsXIJCeG:ydH;zbZMhSXO|YYm= NEToPJcz6oDLzszN M1joblQ5KGh? MoS0bY5lfWOnczCzOE43LcLzMT65NkUh[XCxcITvd4l{ MnqwNlQzPTZ2OUG=
NCI-H1299/pcDNA3 NWrQOWNbS2WubDDWbYFjcWyrdImgRZN{[Xl? MVSwMVIxKG6P MXy5OkBp MYHpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NWjuSWZjOjRzN{ewNVI>
H1299/ICAM-3 MV\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MoHENE0zOCCwTR?= NI\q[VY6PiCq MkPSbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NXW5Sm9HOjRzN{ewNVI>
NCI-H1299/pcDNA3 NIH6R4xHfW6ldHnvckBCe3OjeR?= NXr6NmpYOS93L{GwM|IxyqCwTR?= M1HodFk3KGh? NIm5dWtqdmS3Y3XzJINt\WG4YXflJI9nKGOjc4Dhd4V{NTNuIEisJFktKGGwZDDQRXJR NHX6ZoczPDF5N{CxNi=>
H1299/ICAM-3 NXXLdYpqTnWwY4Tpc44hSXO|YYm= NHn6eoQyNzVxMUCvNlDDqG6P Ml3ZPVYhcA>? NF;rUHpqdmS3Y3XzJINt\WG4YXflJI9nKGOjc4Dhd4V{NTNuIEisJFktKGGwZDDQRXJR MX[yOFE4PzBzMh?=
W1 M3PPXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwMECzNkDPxE1? NF\qUGozPDF2MEG3Oi=>
W1VR MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfXU3NKSzVyPUCuNFU3KM7:TR?= NXLwc3puOjRzNECxO|Y>
K562 M{\wWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwMEOyJOKyKDBwMECxJEDPxE1? NYjzRnhtOjRzM{W5N|c>
K562/ADR MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\XT4FlUUN3ME2zMlI3OSEEsTCwMlQyOiEQvF2= NH;XWFYzPDF|NUmzOy=>
K562 NGficm5CeG:ydH;zbZMhSXO|YYm= NXf4cGxnOC5|IN88US=> NVK1[2xjOjRiaB?= M4L4colv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? M3H2VVI1OTN3OUO3
K562/ADR MVjBdI9xfG:|aYOgRZN{[Xl? NHHYdG8{KM7:TR?= M1z0XVI1KGh? MVjpcoR2[2W|IHHwc5B1d3Orcx?= MYSyOFE{PTl|Nx?=
A549 NXjUcYJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nCO2lEPTB;MD6xNEDDuSByLkCzJO69VQ>? Mo\ENlM6PzFyN{W=
K562 M1i2PWNmdGxiVnnhZoltcXS7IFHzd4F6 NXPP[ppxOy55NfMAl|YxyqCwTR?= NYi5dY1lPzMEoHlCpC=> MX;pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MVGyN|g4PzJ{Mx?=
lucena NXGwUXBqS2WubDDWbYFjcWyrdImgRZN{[Xl? NF3uUWc{Njd34pETOlDDqG6P M3v3dlczyqCqwrC= MXfuc{Bm\m[nY4S= NHvyNWozOzh5N{KyNy=>
FEPS NI\xfpNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MkXUN{44PeLCk{[wxsBvVQ>? Ml:3O|LDqGkEoB?= NXHVfIFrdm9iZX\m[YN1 NFKyNJQzOzh5N{KyNy=>
A2780 Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\BTWM2OD1|LkWgcW0> NH64NXgzOzh{OUKwNy=>
ACHN M1rmWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPwSZVVUUN3MEywMlEhdU1? NF\F[G8zOzh{OUKwNy=>
U-937 MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq5OIVvUUN3MEyzOEBvVQ>? NHPhRpAzOzh{OUKwNy=>
Jurkat MkL3RZBweHSxc3nzJGF{e2G7 MWO1xsDPxGdxbX|CpC=> NXrve3NWOjRiaB?= NXr6NVhJcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= NGrqTY0zOzhzMESwPS=>
Jurkat M2jmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jQUVXDqM7:Zz;tcOKh NET0RWgzPCCq MoCyZZJz\XO2IFr1dotifCClZXzsd{BqdiCJMj;NJJBp[XOn Mom2NlM5OTB2MEm=
Hep-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoC4TWM2OD1yLkC0xtExNjBzIN88US=> MoXwNlM4QDB2MkS=
Hep-2/v MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TUfWlEPTB;MT64xtExNjJyIN88US=> M3i1TVI{PzhyNEK0
SGC-7901 Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHZU2lwOC1zMDFOwIcwdWx? Ml3vNlQwPDhxN{KgbC=> MW\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MV:yN|c1OzV5Mh?=
SGC-7901/VCR MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSwMVExKM7:Zz;tcC=> NH\6U3EzPC92OD:3NkBp NIPNTI1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NFKwfHgzOzd2M{W3Ni=>
SGC-7901 M1nQ[mFxd3C2b4Ppd{BCe3OjeR?= MoPrbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? MWiyN|c1OzV5Mh?=
SGC-7901/VCR NYTMVmoySXCxcITvd4l{KEG|c3H5 M3nnVolv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? NGH2b2UzOzd2M{W3Ni=>
KB-3-1 M2TtWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XQU2lEPTB;MT62OkDDuSByLkG2NkDPxE1? MVmyN|Y4OzR2NR?=
KB-C2 NUn1R4V6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[xVI95UUN3ME2yNFIvPTZiwsGgOFIvPDhzIN88US=> NXX1eJRKOjN4N{O0OFU>
KB-3-1 NHeyd21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPHcYFKSzVyPUGuNlYhyrFiMD6wNlch|ryP NGHOc5czOzZ5M{S0OS=>
KB-V1 M{npWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJyOD64OUDDuSB{MD60JO69VQ>? MXGyN|Y4OzR2NR?=
HEK293/pcDNA3.1 M1j5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLP[YdvUUN3ME2yOE4yKMLzIECuNlA1KM7:TR?= NUDlfIlCOjN4N{O0OFU>
HEK293/ABCB1 Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjjTWdKSzVyPUO1NVIvQCEEsTCzO|gvOzlzIN88US=> MWmyN|Y4OzR2NR?=
A549/EGFP  NXXDb|FXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[3dlVwOC5yMT2xNFAxKM7:TR?= MYDJR|UxRTh4LkegxtEhOjlwMTFOwG0> M13IS|I{PjN2Mkiy
A549/Slug NWH1ZXlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIroVWgxNjBzLUGwNFAh|ryP M1vwWGlEPTB;OT63JOKyKDNwMTFOwG0> M3TNPFI{PjN2Mkiy
JFCR39  NX7FfXQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\FRYoyKML3TR?= NWj2TXlFOjRiaB?= NEnjeVlFVVOR MYPtZZJs\WSueTDpcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCJMj;NJJBp[XOnIHPlcIx{ Mk[zNlM2QTh{N{[=
A549 NV7IOpNCTnWwY4Tpc44hSXO|YYm= NXWwTnREOTByIH7N NUPjNm1HOTZiaB?= M3;2NGROW09? MVzs[YFleyC2bzDhJIxwe3Nib3[gcYlkem:2dXL1cIV{ MYKyN|U6QDJ5Nh?=
SGC7901 Mn3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLrTWM2OD1zLkK25qCKyrIkgJmwMlEyKM7:Zz;tcC=> MkDzNlM2PjR2OEK=
SGC7901/LV-NC NEPobZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;2TWM2OD1zLke35qCKyrIkgJmwMlE3KM7:Zz;tcC=> NYr6XGNrOjN3NkS0PFI>
SGC7901/LV-SGO1 M2DtVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWG4PHpWUUN3ME20MlM36oDLwsJihKkxNjN5IN88[{9udA>? MXOyN|U3PDR6Mh?=
SGC7901/VCR MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\VTWM2Oz1{MD61N-KBkcLz4pEJNU46PiEQvHevcYw> NYi3NmhpOjN3NkS0PFI>
SGC7901/VCR-NC NGe0Z49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPYWFFCUUN3ME2xPU45PuLCidMx5qCKOi5yMTFOwIcwdWx? NFv3[lEzOzV4NES4Ni=>
SGC7901/VCR-si-SGO1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTZwMUlihKnDueLCiUGuNFMh|rypL33s M3vJNlI{PTZ2NEiy
SGC7901/ADR MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHETWM2OD15Lki15qCKyrIkgJmwMlY1KM7:Zz;tcC=> MnfyNlM2PjR2OEK=
SGC7901/ADR-NC MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP5TWM2OD16Lkmz5qCKyrIkgJmwMlY5KM7:Zz;tcC=> NV\ES3h6OjN3NkS0PFI>
SGC7901/ADR-si-SGO1 MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\LVIZIUUN3ME2zMlQ36oDLwsJihKkxNjJ7IN88[{9udA>? NX3PPVhFOjN3NkS0PFI>
SH-SY5Y  MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWmwMlAxOS1zMDFOwG0> MonINlQhcA>? MXXJR|UxRTBwMUGzxtExNjBzMjFOwG0> NGC5UYUzOzF{OUC2OS=>
SH-SY5Y  MnH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTRWmJEOC5yMEGtNVAh|ryP M1v5flQ5KGh? M4LtZmlEPTB;MD6wO|jDuTBwMEC5JO69VQ>? NF;LUZAzOzF{OUC2OS=>
SH-SY5Y  MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj4NE4xODFvMUCg{txO MVq3NkBp M2TkeGlEPTB;MD6wOVHDuTBwMEC4JO69VQ>? M3PIdlI{OTJ7ME[1
SH-SY5Y NVLNW5YzSXCxcITvd4l{KEG|c3H5 NHfySXkxNjFizszN NUfRcVRlOC1{NDDo NG[xZXlqdmS3Y3XzJIFxd3C2b4Ppd{Bw\iCVSD3TXVV[KGOnbHzzJIZwdGyxd3nu[{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCC2aHWgS|IwVSCyaHHz[S=> MnnXNlMyOjlyNkW=
SH-SY5Y NIXkPWFCeG:ydH;zbZMhSXO|YYm= MkjXNE4yKM7:TR?= M{WzOlAuOjRiaB?= M2r4NYlv\HWlZYOgcYl1d3SrYzDhdpJme3UEoB?= MXiyN|EzQTB4NR?=

... Click to View More Cell Line Experimental Data

In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Formulation: Water solutioin
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol <1 mg/mL
In vivo Saline 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
in solvent
Synonyms Leurocristine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03023358 Not yet recruiting Peripheral T Cell Lymphoma Nanfang Hospital of Southern Medical University February 2017 Phase 3
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03003520 Recruiting Lymphoma, Large B-Cell, Diffuse Celgene February 2017 Phase 2
NCT03018626 Not yet recruiting Lymphoma, Large B-Cell, Diffuse Nanfang Hospital of Southern Medical University February 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID